

Skin Disorders: Extremities

Heather Holahan
Dean S. Morrell
Diana B. McShane

REFERENCES

1. White-Chu EF, Conner-Kerr TA: Overview of guidelines for the prevention and treatment of venous leg ulcers: a US perspective. *J Multidiscip Healthc* 7: 111, 2014. [PMID: 24596466]
2. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP: Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. *Medicine* 79: 37, 2000. [PMID: 10670408]
3. Hickman JG, Lazarus GS: Pyoderma gangrenosum: a reappraisal of associated systemic diseases. *Br J Dermatol* 102: 235, 1980. [PMID: 7387878]
4. Thrash B, Menter A: Cutaneous manifestations of gastrointestinal disease: part I. *J Am Acad Dermatol* 68: 189, 2013. [PMID: 23317980]
5. Jeffcoate WJ, Harding KG: Diabetic foot ulcers. *Lancet* 361: 1545, 2003. [PMID: 12737879]
6. Boulton AJ, Kirsner RS, Vileikyte L: Clinical practice. Neuropathic diabetic foot ulcers. *N Engl J Med* 351: 48, 2004. [PMID: 15229307]
7. Richmond NA, Maderal AD, Vivas AC: Evidence-based management of common chronic lower extremity ulcers. *Dermatol Ther* 26: 187, 2013. [PMID: 23742279]
8. Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N: Buruli ulcer and current situation in Japan: a new emerging cutaneous *Mycobacterium* infection. *J Dermatol* 39: 587, 2012. [PMID: 22486235]
9. <http://www.who.int/buruli/country/en/index.html> (Global Buruli Ulcer Initiative, World Health Organization: Buruli ulcer endemic countries.) Accessed June 12, 2013.
10. Stienstra Y, van der Graaf WT, te Meerman GJ, The TH, de Leij LF, van der Werf TS: Susceptibility to development of *Mycobacterium ulcerans* disease: review of possible risk factors. *Trop Med Int Health* 6: 554, 2001. [PMID: 11469950]
11. Silva MT, Portaels F, Pedrosa J: Pathogenetic mechanisms of the intracellular parasite *Mycobacterium ulcerans* leading to Buruli ulcer. *Lancet Infect Dis* 9: 699, 2009. [PMID: 19850228]
12. En J, Goto M, Nakanaga K, et al: Mycolactone is responsible for the painlessness of *Mycobacterium ulcerans* infection (Buruli ulcer) in a murine study. *Infect Immun* 76: 2002, 2008. [PMID: 18316387]
13. Groves R: Unusual cutaneous mycobacterial diseases. *Clin Dermatol* 13: 257, 1995. [PMID: 8521367]
14. Zandieh A, Zandieh B, Dastgheib L: Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. *Int J Dermatol* 52: 59, 2013. [PMID: 23278609]
15. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA: Interventions for American cutaneous and mucocutaneous leishmaniasis. *Cochrane Database Syst Rev* 2: CD004834, 2009. [PMID: 19370612]
16. Eichenfield LF, Tom WL, Chamlin SL, et al: Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol* 70: 338, 2014. [PMID: 24290431]
17. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee: Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 351: 1225, 1998. [PMID: 9643741]
18. Rabinovitz H, Barnhill R: Benign melanocytic neoplasms, in Bologna J, Jorizzo J, Schaffer J, eds: *Dermatology*, 3rd ed. Philadelphia: Mosby Elsevier; 2012:1501.
19. Bailey E, Sober A: Cutaneous melanoma, in Goldsmith L, Katz S, Gichrest B, Paller A, Leffell D, Wolff K (eds): *Fitzpatrick's Dermatology in General Medicine*, 8th ed. New York: McGraw-Hill; 2012.
20. Cole MB, Smith ML: Corns and calluses: environmental and sports-related skin diseases, in Bologna JL, Jorizzo JL, Schaffer JV (eds): *Dermatology*, 3rd ed. Philadelphia: Mosby Elsevier; 2012:1501.
21. Reunala TI: Dermatitis herpetiformis. *Clin Dermatol* 19: 728, 2001. [PMID: 11705682]
22. Thrash B, Patel M, Shah KR, Boland CR, Menter A: Cutaneous manifestations of gastrointestinal disease: part II. *J Am Acad Dermatol* 68: 211, 2013. [PMID: 23317981]
23. Dieterich W, Laag E, Bruckner-Tuderman L, et al: Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. *J Invest Dermatol* 113: 133, 1999. [PMID: 10417632]
24. Beutner EH, Chorzelski TP, Kumar V: Dermatitis herpetiformis—what is it? *Int J Dermatol* 29: 267, 1990. [PMID: 2196234]
25. Caumes E: Treatment of cutaneous larva migrans. *Clin Infect Dis* 30: 811, 2000. [PMID: 10816151]
26. www.cdc.gov/rmsf/symptoms/ (The Centers for Disease Control and Prevention: National Center for Emerging and Zoonotic Infectious Diseases; Division of Vector-Borne Diseases: Rocky Mountain spotted fever updated.) Update September 5, 2013.